EXTENDED - TODAY ONLY: MarketBeat All Access For Just $399 $199 (save 50%)
×
S&P 500   3,957.63 (-0.16%)
DOW   33,852.53 (+0.01%)
QQQ   280.30 (-0.85%)
AAPL   141.15 (-2.13%)
MSFT   240.29 (-0.61%)
META   109.29 (+0.47%)
GOOGL   95.15 (-0.94%)
AMZN   92.30 (-1.76%)
TSLA   180.83 (-1.14%)
NVDA   156.00 (-1.43%)
NIO   10.52 (+3.95%)
BABA   79.73 (+5.07%)
AMD   73.20 (+0.01%)
T   19.00 (+0.96%)
MU   53.71 (-3.66%)
CGC   3.43 (+0.88%)
F   13.75 (+0.15%)
GE   85.55 (+0.09%)
DIS   94.69 (-1.05%)
AMC   7.45 (+1.64%)
PYPL   77.66 (-2.84%)
PFE   49.42 (-0.30%)
NFLX   280.79 (-0.14%)
S&P 500   3,957.63 (-0.16%)
DOW   33,852.53 (+0.01%)
QQQ   280.30 (-0.85%)
AAPL   141.15 (-2.13%)
MSFT   240.29 (-0.61%)
META   109.29 (+0.47%)
GOOGL   95.15 (-0.94%)
AMZN   92.30 (-1.76%)
TSLA   180.83 (-1.14%)
NVDA   156.00 (-1.43%)
NIO   10.52 (+3.95%)
BABA   79.73 (+5.07%)
AMD   73.20 (+0.01%)
T   19.00 (+0.96%)
MU   53.71 (-3.66%)
CGC   3.43 (+0.88%)
F   13.75 (+0.15%)
GE   85.55 (+0.09%)
DIS   94.69 (-1.05%)
AMC   7.45 (+1.64%)
PYPL   77.66 (-2.84%)
PFE   49.42 (-0.30%)
NFLX   280.79 (-0.14%)
S&P 500   3,957.63 (-0.16%)
DOW   33,852.53 (+0.01%)
QQQ   280.30 (-0.85%)
AAPL   141.15 (-2.13%)
MSFT   240.29 (-0.61%)
META   109.29 (+0.47%)
GOOGL   95.15 (-0.94%)
AMZN   92.30 (-1.76%)
TSLA   180.83 (-1.14%)
NVDA   156.00 (-1.43%)
NIO   10.52 (+3.95%)
BABA   79.73 (+5.07%)
AMD   73.20 (+0.01%)
T   19.00 (+0.96%)
MU   53.71 (-3.66%)
CGC   3.43 (+0.88%)
F   13.75 (+0.15%)
GE   85.55 (+0.09%)
DIS   94.69 (-1.05%)
AMC   7.45 (+1.64%)
PYPL   77.66 (-2.84%)
PFE   49.42 (-0.30%)
NFLX   280.79 (-0.14%)
S&P 500   3,957.63 (-0.16%)
DOW   33,852.53 (+0.01%)
QQQ   280.30 (-0.85%)
AAPL   141.15 (-2.13%)
MSFT   240.29 (-0.61%)
META   109.29 (+0.47%)
GOOGL   95.15 (-0.94%)
AMZN   92.30 (-1.76%)
TSLA   180.83 (-1.14%)
NVDA   156.00 (-1.43%)
NIO   10.52 (+3.95%)
BABA   79.73 (+5.07%)
AMD   73.20 (+0.01%)
T   19.00 (+0.96%)
MU   53.71 (-3.66%)
CGC   3.43 (+0.88%)
F   13.75 (+0.15%)
GE   85.55 (+0.09%)
DIS   94.69 (-1.05%)
AMC   7.45 (+1.64%)
PYPL   77.66 (-2.84%)
PFE   49.42 (-0.30%)
NFLX   280.79 (-0.14%)
NASDAQ:BIOL

BIOLASE - BIOL Stock Forecast, Price & News

$0.98
+0.02 (+1.76%)
(As of 11/29/2022 01:46 PM ET)
Add
Compare
Today's Range
$0.96
$0.98
50-Day Range
$0.96
$2.72
52-Week Range
$0.92
$13.83
Volume
992 shs
Average Volume
201,222 shs
Market Capitalization
$6.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.50

BIOLASE MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
872.5% Upside
$9.50 Price Target
Short Interest
Healthy
1.96% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.30mentions of BIOLASE in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.90 out of 5 stars

BIOL stock logo

About BIOLASE (NASDAQ:BIOL) Stock

BIOLASE, Inc., together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, such as cosmetic, restorative, and complex surgical applications. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; diode soft-tissue laser systems for soft tissue, pain therapy, teeth whitening, and cosmetic procedures; and Epic Hygiene laser to manage non-surgical periodontitis and enhance clinical production. It also manufactures and sells consumable products and accessories for its laser systems, as well as markets flexible fibers and hand pieces, and teeth whitening gel kits. The company sells its products through its field sales force and distributor network. The company was formerly known as BIOLASE Technology, Inc. and changed its name to BIOLASE, Inc. in 2012. BIOLASE, Inc. was founded in 1984 and is headquartered in Foothill Ranch, California.

Receive BIOL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BIOLASE and its competitors with MarketBeat's FREE daily newsletter.

BIOL Stock News Headlines

BIOLASE (NASDAQ:BIOL) Coverage Initiated at StockNews.com
BIOLASE NAMES DR. RUSSELL MORROW AS CHIEF DENTAL OFFICER
Biolase Inc
Recap: Biolase Q2 Earnings - Benzinga
See More Headlines
Receive BIOL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BIOLASE and its competitors with MarketBeat's FREE daily newsletter.

BIOL Company Calendar

Last Earnings
11/10/2021
Today
11/29/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/16/2023

Industry, Sector and Symbol

Industry
Dental equipment & supplies
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BIOL
Previous Symbol
NASDAQ:BLTI
Employees
158
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$9.50
High Stock Price Forecast
$14.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+872.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-16,160,000.00
Pretax Margin
-51.17%

Debt

Sales & Book Value

Annual Sales
$39.19 million
Book Value
$4.11 per share

Miscellaneous

Free Float
6,996,000
Market Cap
$6.98 million
Optionable
Not Optionable
Beta
1.45

Key Executives

  • Mr. John R. Beaver (Age 61)
    Pres, CEO & Director
    Comp: $876.18k
  • Ms. Jennifer Bright
    Chief Financial Officer
  • Mr. Steven Sandor
    Chief Operating Officer
  • Mr. Matthew Wilson
    VP of HR
  • Dr. Russell Morrow D.D.S.
    Chief Dental Officer
  • Mr. Michael C. Carroll (Age 50)
    Corp. Sec.
  • Mr. David Rodriguez
    Director of Education & Events













BIOL Stock - Frequently Asked Questions

Should I buy or sell BIOLASE stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BIOLASE in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BIOL shares.
View BIOL analyst ratings
or view top-rated stocks.

What is BIOLASE's stock price forecast for 2023?

3 equities research analysts have issued 1-year price objectives for BIOLASE's stock. Their BIOL share price forecasts range from $5.00 to $14.00. On average, they anticipate the company's stock price to reach $9.50 in the next year. This suggests a possible upside of 872.5% from the stock's current price.
View analysts price targets for BIOL
or view top-rated stocks among Wall Street analysts.

How have BIOL shares performed in 2022?

BIOLASE's stock was trading at $9.75 at the beginning of the year. Since then, BIOL shares have decreased by 90.0% and is now trading at $0.9769.
View the best growth stocks for 2022 here
.

Are investors shorting BIOLASE?

BIOLASE saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 137,500 shares, an increase of 8.4% from the October 31st total of 126,900 shares. Based on an average daily trading volume, of 77,600 shares, the days-to-cover ratio is presently 1.8 days. Currently, 2.0% of the company's stock are short sold.
View BIOLASE's Short Interest
.

When is BIOLASE's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 16th 2023.
View our BIOL earnings forecast
.

How were BIOLASE's earnings last quarter?

BIOLASE, Inc. (NASDAQ:BIOL) posted its earnings results on Wednesday, November, 10th. The medical technology company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.25. The medical technology company earned $9.53 million during the quarter. BIOLASE had a negative net margin of 51.38% and a negative trailing twelve-month return on equity of 118.42%. During the same period in the previous year, the business earned ($5.25) EPS.

When did BIOLASE's stock split?

BIOLASE's stock reverse split before market open on Friday, April 29th 2022. The 1-25 reverse split was announced on Friday, April 29th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What guidance has BIOLASE issued on next quarter's earnings?

BIOLASE updated its fourth quarter 2022 earnings guidance on Thursday, November, 10th. The company provided EPS guidance of for the period. The company issued revenue guidance of $13.00M-, compared to the consensus revenue estimate of $12.55 million.

What is John R. Beaver's approval rating as BIOLASE's CEO?

4 employees have rated BIOLASE Chief Executive Officer John R. Beaver on Glassdoor.com. John R. Beaver has an approval rating of 13% among the company's employees. This puts John R. Beaver in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 35.0% of employees surveyed would recommend working at BIOLASE to a friend.

What other stocks do shareholders of BIOLASE own?
What is BIOLASE's stock symbol?

BIOLASE trades on the NASDAQ under the ticker symbol "BIOL."

Who are BIOLASE's major shareholders?

BIOLASE's stock is owned by a variety of institutional and retail investors. Top institutional investors include Armistice Capital LLC (10.20%), Perkins Capital Management Inc. (1.93%), Essex Investment Management Co. LLC (1.47%) and Citadel Advisors LLC (0.25%). Insiders that own company stock include Jack W Schuler, John R Beaver, John R Beaver, Jonathan T Md Lord and Larry N Feinberg.
View institutional ownership trends
.

How do I buy shares of BIOLASE?

Shares of BIOL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BIOLASE's stock price today?

One share of BIOL stock can currently be purchased for approximately $0.98.

How much money does BIOLASE make?

BIOLASE (NASDAQ:BIOL) has a market capitalization of $6.98 million and generates $39.19 million in revenue each year. The medical technology company earns $-16,160,000.00 in net income (profit) each year or ($3.57) on an earnings per share basis.

How many employees does BIOLASE have?

The company employs 158 workers across the globe.

How can I contact BIOLASE?

BIOLASE's mailing address is 27042 Towne Center Drive Suite 270, Lake Forest CA, 92610. The official website for the company is www.biolase.com. The medical technology company can be reached via phone at (949) 361-1200, via email at rcaron@dresnerallencaron.com, or via fax at 949-273-6677.

This page (NASDAQ:BIOL) was last updated on 11/29/2022 by MarketBeat.com Staff